Your browser doesn't support javascript.
loading
Identification of PANoptosis-related signature reveals immune infiltration characteristics and immunotherapy responses for renal cell carcinoma.
Xu, Yan; Hua, Jingqi; Que, Hongliang; Zeng, Tengyue; Li, Quan; Deng, Junpeng; Xie, Jianjun.
Affiliation
  • Xu Y; Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, China.
  • Hua J; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China.
  • Que H; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China.
  • Zeng T; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China.
  • Li Q; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China.
  • Deng J; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China. djunpeng@outlook.com.
  • Xie J; Department of Urology, Suzhou Municipal Hospital, Suzhou, 215001, China. uro_xiejianjun@163.com.
BMC Cancer ; 24(1): 292, 2024 Mar 04.
Article in En | MEDLINE | ID: mdl-38439022
ABSTRACT
PANoptosis is a specific type of inflammatory programmed cell death (PCD) modality that can be involved in three key modes of cellular programmed cell death-pyroptosis, apoptosis and necroptosis. We analyzed PANoptosis activity in three common renal cell carcinoma subtypes (Clear cell renal cell carcinoma, Papillary renal cell carcinoma, and Chromophobe renal cell carcinoma) separately and constructed a new PANoptosis immunity index (PANII). In three renal cell carcinomas, we found that PANII was an effective predictor of immunotherapy efficacy in KIRC, KIRP and KICH, and the high PANII group was characterized by high immune infiltration and sensitivity to immunotherapy, while the low PANII group was prone to immune escape and immunotherapy resistance. We performed molecular docking prediction of each core protein comprising PANII and identified natural small molecule compounds with the highest affinity to target proteins. In addition, we found that down-regulation of PYCARD inhibited the proliferation and migration of renal clear cell carcinoma cells by in vitro functional assays, suggesting that PYCARD could be a novel target for renal clear cell carcinoma therapy. Our findings that the PANoptosis characterization-based index (PANII) helps to elucidate the tumor microenvironmental features of three common renal cell carcinoma subtypes and identify patient populations that will benefit from immunotherapy, providing a new tool for the clinical diagnosis and treatment of patients with intermediate- and advanced-stage renal cell carcinoma.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication: